ED
LLY icon

Exane Derivatives’s Eli Lilly LLY Stock Holding History

Exane Derivatives’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$256K Sell
790
-1,691
-68% -$508K 0.15% 141
2022
Q1 		$710K Buy
2,481
+688
+38% +$177K 0.2% 132
2021
Q4 		$495K Buy
1,793
+43
+2% +$10.9K 0.12% 179
2021
Q3 		$404K Buy
1,750
+252
+17% +$62.2K 0.1% 223
2021
Q2 		$352K Buy
1,498
+101
+7% +$20.3K 0.08% 249
2021
Q1 		$261K Sell
1,397
-2,653
-66% -$519K 0.07% 253
2020
Q4 		$684K Buy
4,050
+2,932
+262% +$438K 0.2% 109
2020
Q3 		$165K Sell
1,118
-2,695
-71% -$417K 0.05% 228
2020
Q2 		$626K Sell
3,813
-1,550
-29% -$238K 0.17% 111
2020
Q1 		$744K Sell
5,363
-411
-7% -$56.5K 0.21% 95
2019
Q4 		$815K Sell
5,774
-763
-12% -$88.4K 0.15% 114
2019
Q3 		$731K Buy
6,537
+5,549
+562% +$618K 0.13% 126
2019
Q2 		$109K Buy
988
+70
+8% +$8.24K 0.02% 325
2019
Q1 		$119K Sell
918
-8,717
-90% -$1.06M 0.02% 278
2018
Q4 		$1.11M Sell
9,635
-2,329
-19% -$260K 0.2% 113
2018
Q3 		$1.28M Sell
11,964
-3,166
-21% -$317K 0.24% 91
2018
Q2 		$1.29M Sell
15,130
-1,227
-8% -$101K 0.22% 96
2018
Q1 		$1.26M Sell
16,357
-2,330
-12% -$188K 0.25% 98
2017
Q4 		$1.58M Buy
18,687
+18,051
+2,838% +$1.54M 0.27% 66
2017
Q3 		$54.4K Sell
636
-3,055
-83% -$251K 0.01% 300
2017
Q2 		$304K Sell
3,691
-1,675
-31% -$137K 0.07% 174
2017
Q1 		$451K Sell
5,366
-12,426
-70% -$995K 0.1% 138
2016
Q4 		$1.31M Buy
17,792
+16,897
+1,888% +$1.26M 0.26% 76
2016
Q3 		$71.8K Sell
895
-2,584
-74% -$207K 0.01% 265
2016
Q2 		$274K Sell
3,479
-2,396
-41% -$180K 0.05% 179
2016
Q1 		$423K Buy
5,875
+3,653
+164% +$276K 0.06% 146
2015
Q4 		$187K Buy
+2,222
New +$184K 0.03% 163

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Exane Derivatives's LLY Position: Q2 2022 in Review

Exane Derivatives reduced its Eli Lilly (LLY) stake by 68% in Q2 2022, selling an estimated $508K and leaving 790 shares worth $256K. The position accounts for 0.15% of the portfolio, ranked #141.

Exane Derivatives first reported a position in LLY in Q4 2015 and has held it in 27 quarters since. The position peaked at $1.58M in Q4 2017. 2,445 funds tracked by Wall St. Rank hold LLY as of Q2 2022.

  • Exane Derivatives held 790 shares of Eli Lilly worth $256K as of Q2 2022.
  • Exane Derivatives sold 1,691 Eli Lilly shares in Q2 2022, an estimated $508K.
  • Eli Lilly made up 0.15% of Exane Derivatives's portfolio in Q2 2022, its #141 holding.
  • Exane Derivatives first reported a position in Eli Lilly in Q4 2015 and has held it in 27 quarters since.
  • Exane Derivatives's Eli Lilly position peaked at $1.58M in Q4 2017.
  • 2,445 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.